Bagsværd, Denmark. November 5, 2026 – Novo Nordisk A/S has announced significant share transactions by its board members and executives, highlighting ongoing confidence in the company’s future. The transactions were reported in compliance with Article 19 of Regulation No. 596/2014 on market abuse, demonstrating the company’s commitment to transparency and regulatory adherence.

The filing indicates that Martin Holst Lange, the Executive Vice President and Chief Scientific Officer, was involved in the sale of 12,000 shares at a price of DKK 285.00 each, totaling approximately DKK 3,420,000. This transaction was executed on November 4, 2026, at Nasdaq Copenhagen.

Background

Founded in 1923, Novo Nordisk A/S is a global healthcare company headquartered in Bagsværd, Denmark. The company specializes in the development and production of pharmaceutical preparations, particularly in diabetes care and hormone replacement therapy. Novo Nordisk is listed on the New York Stock Exchange (ticker: NVO) and on Nasdaq Copenhagen (ticker: Novo -B). The company is classified under the Standard Industrial Classification (SIC) code 2834, which pertains to pharmaceutical preparations.

What the Filing Says

The recent filing, with accession number 0001171843-26-007156, outlines the details of the share transactions conducted by board members and executives. It states, "The company’s board members, executives and their associated persons have reported the transactions to Novo Nordisk and have given Novo Nordisk power of attorney to publish the transactions on their behalf." This emphasizes the company’s adherence to ethical trading practices.

Impact

This report may affect stakeholders, including investors and regulatory bodies, by reinforcing confidence in Novo Nordisk's governance and transparency. The transactions signal a positive outlook from company executives, which may influence investor sentiment and market perception.

What's Next

The filing does not specify any further actions or upcoming events related to these transactions.